Atrial fibrillation: How to approach rate control
- Lynda E. Rosenfeld MD
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The optimal management of atrial fibrillation is of considerable clinical importance, and with the recent publication of four studies suggesting the equivalence of rate and rhythm control strategies, new attention has been focused on rate control. Reasons for rate control include reduction of symptoms and the prevention of tachycardia-mediated cardiomyopathy; yet, evidence-based definitions of optimal rate control are lacking. This article examines an approach to rate control that includes serial assessment of heart rate and symptoms, both at rest and with exertion, and the use of therapy tailored to the individual and modified over time (as no single therapy demonstrates clear superiority). Often, multidrug regimens including digoxin and a calcium channel blocker or β-blocker are required, and in a minority of patients atrioventricular nodal ablation and pacing are necessary. Several novel therapies currently under development are also discussed.
- The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation: Atrial fibrillation: current understandings and research imperatives. J Am Coll Cardiol 1993, 22:1830–1834. CrossRef
- Hohnloser SH, Kuck K-H, Lillienthal J, for the PIAF Investigators: Rhythm or rate control in atrial fibrillation-Pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet 2000, 356:1789–1794. CrossRef
- Carlsson J, Miketic S, Windeier J, et al.: Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation. J Am Coll Cardiol 2003, 41:1690–1696. CrossRef
- The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825–1833. AFFIRM is the largest of the recent randomized trials suggesting that rhythm and rate control strategies for AF have similar outcomes. It is the only one that rigorously defines rate control both at rest and with exertion. CrossRef
- Van GelderIC, Hagens VE, Bosker HA, et al.: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002, 347:1834–1840. The RACE study is a smaller study than AFFIRM. It also concludes that rate control is not inferior to rhythm control in AF. Endpoints are death and morbidity from cardiovascular causes. Rate control is only defined at rest. CrossRef
- Kerr C, Boone I, Connolly S: Follow up of atrial fibrillation: The initial experience of the Canadian registry of atrial fibrillation. Eur Heart J 1996, 17-SuppC:48–51.
- Gossage AM, Braxton Hicks JA: On auricular fibrillation. Quart J Med 1913, 6:435–440.
- Brill IC: Auricular fibrillation with congestive failure and no other evidence of organic heart disease. Am Heart J 1937, 13:175–182. CrossRef
- Phillips E, Levine SA: Auricular fibrillation without other evidence of heart disease. Am J Med 1949, 7:478–489. CrossRef
- Grogan M, Smith HC, Gersh BJ, Wood DL: Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992, 69:1570–1573. CrossRef
- Kieny JR, Sacrez A, Facello A, et al.: Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J 1992, 13:1290–1295.
- Fenelon G, Wijns W, Andries E, Brugada P: Tachycardiomyopathy: Mechanisms and clinical implications. PACE 1996, 19:95–106.
- Shinbane JS, Wood MA, Jensen DN, et al.: Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies. J Am Coll Cardiol 1997, 29:709–715. CrossRef
- Redfield MM, Kay GN, Jenkins LS, et al.: Tachycardia-related cardiomyopathy: A common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 2000, 75:790–795.
- Umana E, Solares A, Alpert MA: Tachycardia-induced cardiomyopathy. Am J Med 2003, 114:51–55. CrossRef
- Packer DL, Bardy GH, Worley SJ, et al.: Tachycardia-induced cardiomyopathy: A reversible form of left ventricular dysfunction. Am J Cardiol 1986, 57:563–570. CrossRef
- Rawles JM: What is meant by a "controlled" ventricular rate in atrial fibrillation? Br Heart J 1990, 63:157–161.
- Levy S, Breithardt G, Campbell RWE et al.: Atrial fibrillation: current knowledge and recommendations for management. Eur Heart J 1998, 19:1294–1320. CrossRef
- Luderitz B, Jung W: Quality of life in patients with atrial fibrillation. Arch Intern Med 2000, 160:1749–1757. CrossRef
- Page RL: Newly diagnosed atrial fibrillation. N Engl J Med 2004, 351:2408–2416. CrossRef
- Olshansky B, Rosenfeld LE, Warner AL, et al.: The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004, 43:1201–1208. This substudy of the AFFIRM investigation compares different strategies in rate control. It concludes that rate control is achievable in the majority of patients with medical therapy, but often requires both dosage and medication changes, and frequently necessitates multi-drug regimens, β-blockers, with or without digoxin, were the most effective rate-controlling drugs. CrossRef
- Snow V, Weiss KB, LeFevre M, et al.: Management of newly detected atrial fibrillation: A clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003, 139:1009–1017.
- American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences: ACCJAHAJESC guidelines for the management of patients with atrial fibrillation: Executive summary. J Am Coll Cardiol 2001, 38:1231–1265. This extensive review offers guidelines for various aspects of the management of AF, as well as their justification. It recommends assessing heart rate both at rest and with exercise and states "The rate is generally considered controlled when the ventricular response is between 60 and 80 bpm at rest and between 90 to 115 during moderate exercise". CrossRef
- Williamson BD, Man KC, Daoud E, et al.: Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 1994, 331:910–917. CrossRef
- Kirsh JA, Sahakian AV, Baerman JM, Swiryn S: Ventricular response to atrial fibrillation: Role of atrioventricular conduction pathways. J Am Coll Cardiol 1988, 12:1265–1272. CrossRef
- Pritchett ELC: Management of atrial fibrillation. New Engl J Med 1992, 326:1264–1271. CrossRef
- Kowey PR: You only have so many heartbeats. J Am Coll Cardiol 2004, 43:1209–1210. CrossRef
- Gold H, Kwit NT, Otto H, Fox T: Physiological adaptions in cardiac slowing by digitalis and their bearing on problems of digitalization in patients with auricular fibrillation. J Pharmacol Exp Ther 1939, 67:224–238.
- Beasley R, Smith DA, McHaffie DJ: Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. Br Med J 1985, 290:9–11. CrossRef
- David D, Di Segni E, Klein HO, Kaplinsky E: Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: Beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol 1979, 44:1378–1382. CrossRef
- Lewis RV, Laing E, Moreland TA, et al.: A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. Eur Heart J 1988, 9:279–283.
- Lewis RV, Irvine N, McDevitt DG: Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J 1988, 9:777–781.
- Galun E, Flugelman MY, Glickson M, Eliakim M: Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest 1991, 99:1038–1040.
- Rawles JM, Metcalfe MJ, Jennings K: Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J 1990, 63:225–227.
- Falk RH: Ventricular rate control in the elderly: Is digoxin enough? AJGC 2002, 11:353–356.
- Lundstrom T, Ryden L: Ventricular rate control and exercise performance in chronic atrial fibrillation: Effects of diltiazem and verapamil. J Am Coll Cardiol 1990, 16:86–90. CrossRef
- Lang R, Klein HO, Di Segni E, et al.: Verapamil improves exercise capacity in chronic atrial fibrillation: Double-blind crossover study. Am Heart J 1983, 105:820–825. CrossRef
- Klein HO, Pauzner H, Di Segni E, et al.: The beneficial effects of verapamil in chronic atrial fibrillation. Arch Intern Med 1979, 139:747–749. CrossRef
- Atwood JE, Myers JN, Sullivan MJ, et al.: Diltiazem and exercise performance in patients with chronic atrial fibrillation. Chest 1988, 92:20–25.
- Roth A, Harrison E, Mitani G, et al.: Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986, 73:316–324.
- Botto GL, Bonini W, Broffoni T: Modulation of ventricular rate in permanent atrial fibrillation: Randomized, crossover study of the effects of slow-release formulations of gallopamil, diltiazem, or verapamil. Clin Cardiol 1998, 21:837–840.
- Farshi R Kistner D, Sarma JSM, et al.: Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens. J Am Coll Cardiol 1999, 33:304–310. CrossRef
- DiBianco R, Morganroth J, Freitag JA, et al.: Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J 1984, 108:1121–1127. CrossRef
- Lewis RV, McMurray J, McDevitt DG: Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol 1989, 13:1–6. CrossRef
- Joglar JA, Acusta AP, Shusterman NH, et al.: Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001, 142:498–501. CrossRef
- Roth A, Kaluski E, Feiner S, et al.: Clonidine for patients with rapid atrial fibrillation. Ann Intern Med 1992, 116:388–390.
- Gallagher JJ, Svenson RH, Kasell JH, et al.: Catheter technique for closed-chest ablation of the atrioventricular conduction system. N Engl J Med 1982, 306:194–200. CrossRef
- Brignole M, Gianfranchi L, Menozzi C, et al.: Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation. Circulation 1997, 96:2617–2624.
- Zhang Y, Mazgalev TN: Ventricular rate control during atrial fibrillation and AV node modifications: Past, present, and future. PACE 2004, 27:382–393. This article examines both current and exciting potential future therapies for rate control in AF.
- Brignole M, Menozzi C, Gianfranchi L, et al.: Assessment of atrioventricular junction ablation and WIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation. Circulation 1998, 98:953–960.
- Scheinman MM, Morady F: Nonpharmacological approaches to atrial fibrillation. Circulation 2001, 103:2120–2125.
- Weerasooriya R, Davis M, Powell A, et al.: The Australian intervention randomized control of rate in atrial fibrillation trial (AIRCRAFT). J Am Coll Cardiol 2003, 41:1697–1702. CrossRef
- Zhuang S, Zhang Y, Mowrey KA, et al.: Ventricular rate control by selective vagal stimulation is superior to rhythm regularization by atrioventricular nodal ablation and pacing during atrial fibrillation. Circulation 2002, 106:1853–1858. CrossRef
- Atrial fibrillation: How to approach rate control
Current Cardiology Reports
Volume 7, Issue 5 , pp 391-397
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Section of Cardiovascular Medicine 3 FMP, Yale University School of Medicine, 333 Cedar Street, 06510, New Haven, CT, USA